SCHEMBL10116599

SCHEMBL10116599

Cc1c(NC(=O)c2ccc(NS(=O)(=O)C(C)C)cc2)ccc2c1CCC2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
SIRT5 Q9NXA8 1/20 0.39
LMNA P02545 3/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.36
MAPT P10636 4/20 0.36
ALDH1A1 P00352 4/20 0.35
HPGD P15428 4/20 0.34
MAPK10 P53779 1/20 0.34
MAPK1 P28482 1/20 0.34
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA4 P48058 1/20 0.34
NAMPT P43490 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
FLT3 P36888 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116333 0.85 CASP3 (0.39) CASP3SENP8SENP7SENP6SIRT5
SCHEMBL10116591 0.82 LMNA (0.40) CASP3SENP8SENP7SENP6SIRT5
SCHEMBL11936098 0.80 PARP1 (0.36)
SCHEMBL10116592 0.80 ALDH1A1 (0.44) LMNAKDM4EHTTMAPTALDH1A1
SCHEMBL10116588 0.76 ALDH1A1 (0.41) LMNAKDM4EMAPTALDH1A1HPGD
SCHEMBL10116637 0.76 LMNA (0.41) LMNAKDM4EHTTMAPTALDH1A1
SCHEMBL10116630 0.74 RAB9A (0.40) LMNAKDM4EHTTMAPTALDH1A1
SCHEMBL10116662 0.73 HPGD (0.45) LMNAKDM4EHTTMAPTHPGD
SCHEMBL10115472 0.73 ALDH1A1 (0.37) LMNAALDH1A1
SCHEMBL10116032 0.73 CCR8 (0.41) LMNAMAPTMAPK1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R CASP3 3162/4885SENP8 1934/4885SENP7 673/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R CASP3 2857/4885SENP8 1755/4885SENP7 604/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R CASP3 3198/4885SENP8 2116/4885SENP7 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.